ISAL 2019 | Azacitidine maintance to improve DFS in elderly AML: HOVON-97 results

Bob Löwenberg

The HOVON-97 study (Netherlands Trial Registry NTR1810; EudraCT 2008-001290-15) investigated the use of azacitidine maintenance following intensive chemotherapy in older patients with acute myeloid leukemia (AML). We spoke to Bob Löwenberg, MD, PhD, of Erasmus University Medical Centre, Rotterdam, Netherlands, about the recently published results. This interview took place at the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany.

Share this video